Bridgepoint Development Capital To Acquire Quotient Clinical - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Bridgepoint Development Capital To Acquire Quotient Clinical

Source: Applied Clinical Trials

Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital.

Quotient's platform, which "offers an integrated approach to formulation development, 'real-time' drug product manufacturing and clinical testing," has been proven to reduce the time and cost of early stage drug development. A global company, Quotient has two primary facilities in the UK, and more that 3/4 of its revenues are from customers in the US or mainland Europe.

The financial details of the acquisition were undisclosed.

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here